Riga-based Cellbox Labs, growing miniature human organ replicas outdoors the physique, has secured €3.3 million in non-dilutive funding to speed up the event of its dynamic organ-on-a-chip know-how.
A part of this funding comes from state assist underneath the Vital Undertaking of Widespread European Curiosity (IPCEI) within the healthcare sector, often known as “Tech4Cure”, which strengthens EU industrial resilience and reinforces the Single Market.
The corporate famous in a public assertion: “Personalised gut-on-chip programs are key to precisely predicting particular person responses to medicine, meals, and probiotics, unlocking new worth for the pharma, vitamin, and purposeful meals industries.”
Based in 2020 by Artūrs Ābols, Gatis Mozoļevskis, and Roberts Rimša, Cellbox Labs specialises in creating organ-on-chip programs; micro-engineered setups that separate endothelial and epithelial layers with a permeable membrane. This enables the modelling of organs such because the kidney, intestine, lung, blood-brain barrier, and pancreas, utilizing non-absorbing supplies optimised for drug discovery.
The platform helps managed fuel situations, is mass manufactured for reproducibility, and options an automatic system that reduces guide work whereas enabling scalable throughput from 8 to 24 chips.
The funding will likely be channelled into 4 key initiatives.
- First, in collaboration with Altis Biosystems, Cellbox Labs will scale an automatic, major cell-based gut-on-chip mannequin for pharmaceutical throughput, shifting in direction of personalised fashions utilizing induced pluripotent stem cells (iPSCs) and patient-derived microbiota.
- Second, the corporate will combine oxygen and pH sensors immediately into each organ-on-chip assay, producing stay knowledge with out further {hardware}. This matches the business shift in direction of richer datasets for AI-driven drug discovery.
- Third, the workforce will benchmark biosimilar efficiency by testing GLP-1 generics on pancreatic islet organ-on-chip programs underneath dynamic move, evaluating outcomes with static cultures and animal fashions to enhance the physiological relevance of biosimilar testing.
- Fourth, alongside ESQlabs and MPSlabs, Cellbox Labs will develop high-fidelity digital twin fashions of its in vitro programs, integrating them with physiologically based mostly human fashions to allow in vitro–in vivo translation (IVIVE). This goals to strengthen the predictive energy of organ-on-chip platforms for human outcomes.
This strategic roadmap aligns with regulatory developments such because the FDA’s plan to section out animal testing necessities for sure medicine and the NIH’s mandate to incorporate laptop modelling, AI, and organ-on-chip applied sciences in funded analysis.
The startup had beforehand raised €935k in a 2024 pre-Seed spherical led by Latvian Buildit VC, with participation from LatBAN angels, ASP Asset Administration AIFP, and personal investor Ansis Spridzans.
With its newest capital injection, Cellbox Labs goals to speed up its push for predictive, data-rich, and personalised drug testing platforms – with out counting on animal trials.
